This commentary reviews the evolution of the process of cancer research in the United States over the past 6 decades, from an academic-based to drug industry-based research, and the advantages and concerns. It proposes a new form of cancer research that involves the tumor-specific cancer researchers as the primary drivers of the process, and outlines the benefits of such a model in relation to potential improved cost benefits, success rates, and research time lines.